Tissue-based biomarkers predicting outcomes in metastatic colorectal cancer: A review

Clinical and Translational Oncology

Volumn 16, Issue 5, 2014, Pages 425-435

  Ung, L ^a   Lam, A K Y ^b   Morris, D L ^a   Chua, T C ^a,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

^c Manly Hospital Northern Sydney Local Health District ^*  (Australia)

Author keywords

Chemotherapy; Metastatic colorectal cancer; Tumour markers

Indexed keywords

B RAF KINASE; BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CETUXIMAB; CHEMOKINE RECEPTOR CXCR4; DIHYDROPYRIMIDINE DEHYDROGENASE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; GELATINASE A; IRINOTECAN; MATRIX METALLOPROTEINASE; OXALIPLATIN; PANITUMUMAB; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; RALTITREXED; SOMATOMEDIN B; SORAFENIB; SUNITINIB; THYMIDINE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; UNINDEXED DRUG; UVOMORULIN; VASCULOTROPIN;

ANEUPLOIDY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CAPILLARY DENSITY; CHROMOSOME 18Q; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG TREATMENT FAILURE; GENE MUTATION; GENOMIC INSTABILITY; HETEROZYGOSITY LOSS; HUMAN; METASTASIS RESECTION; METASTATIC COLORECTAL CANCER; MICROSATELLITE INSTABILITY; NONHUMAN; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PREDICTION; PROGRESSION FREE SURVIVAL; PYRIMIDINE METABOLISM; REVIEW; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; CELL CYCLE; COLORECTAL TUMOR; GENETICS; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); ONCOGENE; PATHOLOGY; PROGNOSIS;

CELL CYCLE; COLORECTAL NEOPLASMS; GENES, TUMOR SUPPRESSOR; GENOMIC INSTABILITY; HUMANS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENES; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84900824816     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-013-1154-6     Document Type: Review

References (94)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Stangl R, Altendorf-Hofmann A, Charnley R, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet. 1994;343:1405-10.
3. McLeod HL, Murray GI. Tumour markers of prognosis in colorectal cancer. Br J Cancer. 1999;79:191-203.
4. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al. American society of clinical oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27:2091-6.
5. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313-27.
6. Munro A, Lain S, Lane D. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer. 2005;92:434-44.
7. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 2009;9:489-99.
8. Andreyev HJN, Norman AR, Clarke PA, Cunningham D, Oates JR. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst. 1998;90:675-84.
9. Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer. 2001;1:55-67.
10. Morrin M, Kelly M, Barrett N, Delaney P. Mutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance. Gut. 1994;35:1627-31.
11. Andreyev H, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer. 2001;85:692.
12. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26:374-9.
13. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757-65.
14. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408-17.
15. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-34.
16. Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer. 2012;48:1466-75.
17. Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol. 2012;30:3570-7.
18. Miranda E, Bianchi P, Destro A, Morenghi E, Malesci A, Santoro A, et al. Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases. Cancer. 2013;119:266-76.
19. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-54.
20. Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011;117:4623-32.
21. Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med. 2009;361:98-9.
22. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26:5705-12.
23. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol. 2004;22:529-36.
24. Etienne M-C, Chazal M, Laurent-Puig P, Magné N, Rosty C, Formento J-L, et al. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol. 2002;20:2832-43.
25. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol. 1997;15:3223-9.
26. Edler D, Hallstrom M, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H. Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. Clin Cancer Res. 2000;6:1378-84.
27. Bathe O, Franceschi D, Livingstone A, Moffat F, Tian E, Ardalan B. Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: implications for chemotherapeutic options and survival. Cancer J Sci Amer. 1999;5:34.
28. Gonen M, Hummer A, Zervoudakis A, Sullivan D, Fong Y, Banerjee D, et al. Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. J Clin Oncol. 2003;21:406-12.
29. Ichikawa W, Uetake H, Shirota Y, Yamada H, Takahashi T, Nihei Z, et al. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine- based chemotherapy for metastatic colorectal cancer. Br J Cancer. 2003;89:1486-92.
30. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 2000;6:1322-7.
31. Meropol NJ, Gold PJ, Diasio RB, Andria M, Dhami M, Godfrey T, et al. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2006;24:4069-77.
32. Daniel CR, Bostick RM, Flanders WD, Long Q, Fedirko V, Sidelnikov E, et al. TGF-a expression as a potential biomarker of risk within the normal-appearing colorectal mucosa of patients with and without incident sporadic adenoma. Cancer Epidemiol Biom Prev. 2009;18:65-73.
33. Saeki T, Salomon DS, Johnson GR, Gullick WJ, Mandai K, Yamagami K, et al. Association of epidermal growth factor-related peptides and type I receptor tyrosine kinase receptors with prognosis of human colorectal carcinomas. Jpn J Clin Oncol. 1995;25:240-9.
34. De Jong KP, Stellema R, Karrenbeld A, Koudstaal J, Gouw AS, Sluiter WJ, et al. Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. Hepatology. 1998;28:971-9.
35. Barozzi C, Ravaioli M, D'Errico A, Grazi GL, Poggioli G, Cavrini G, et al. Relevance of biologic markers in colorectal carcinoma: a comparative study of a broad panel. Cancer. 2002;94:647-57.
36. Neal C, Garcea G, Doucas H, Manson M, Sutton C, Dennison A, et al. Molecular prognostic markers in resectable colorectal liver metastases: a systematic review. Eur J Cancer. 2006;42:1728-43.
37. Lam AK, Ong K, Ho YH. hTERT expression in colorectal adenocarcinoma: correlations with p21, p53 expressions and clinicopathological features. Int J Colorect Dis. 2008;23:587-94.
38. Tullo A, D'Erchia AM, Honda K, Mitry RR, Kelly MD, Habib NA, et al. Characterization of p53 mutations in colorectal liver metastases and correlation with clinical parameters. Clin Cancer Res. 1999;5:3523-8.
39. Yang Y, Forslund A, Remotti H, Lönnroth C, Andersson M, Brevinge H, et al. p53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection. Cancer. 2001;91:727-36.
40. Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner GJ, et al. Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. J Clin Oncol. 2009;27:4591-8.
41. Watanabe T, Wu T-T, Catalano PJ, Ueki T, Satriano R, Haller DG, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med. 2001;344:1196-206.
42. Jen J, Kim H, Piantadosi S, Liu Z-F, Levitt RC, Sistonen P, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med. 1994;331:213-21.
43. Carethers JM, Hawn MT, Greenson JK, Hitchcock CL, Boland CR. Prognostic significance of allelic loss at chromosome 18q21 for stage II colorectal cancer. Gastroenterology. 1998;114:1188-95.
44. Parsons R, Myeroff LL, Liu B, Willson JK, Markowitz SD, Kinzler KW, et al. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res. 1995;55:5548-50.
45. Xu Y, Pasche B. TGF-b signalling alterations and susceptibility to colorectal cancer. Hum Mol Genet. 2007;16 Spec No 1:R14-20.
46. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342:1350-8.
47. Robson H, Anderson E, James RD, Schofield PF. Transforming growth factor beta 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients. Br J Cancer. 1996;74:753.
48. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, et al. Inactivation of the type II TGF-b receptor in colon cancer cells with microsatellite instability. Science. 1995;268:1336-8.
49. Shim KS, Kim KH, Han WS, Park EB. Elevated serum levels of transforming growth factor-b1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection. Cancer. 1999;85:554-61.
50. Tsushima H, Ito N, Tamura S, Matsuda Y, Inada M, Yabuuchi I, et al. Circulating transforming growth factor b1 as a predictor of liver metastasis after resection in colorectal cancer. Clin Cancer Res. 2001;7:1258-62.
51. Chapman MA, Hardcastle JD, Armitage NC. Five-year prospective study of DNA tumor ploidy and colorectal cancer survival. Cancer. 1995;76:383-7.
52. Bauer KD, Bagwell CB, Giaretti W, Melamed M, Zarbo RJ, Witzig TE, et al. Consensus review of the clinical utility of DNA flow cytometry in colorectal cancer. Cytometry. 1993;14:486-91.
53. Nakao K, Shibusawa M, Ishihara A, Yoshizawa H, Tsunoda A, Kusano M, et al. Genetic changes in colorectal carcinoma tumors with liver metastases analyzed by comparative genomic hybridization and DNA ploidy. Cancer. 2001;91: 721-6.
54. Walther A, Houlston R, Tomlinson I. Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut. 2008;57: 941-50.
55. Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med. 2000;342:69-77.
56. Boland CR. Clinical uses of microsatellite instability testing in colorectal cancer: an ongoing challenge. J Clin Oncol. 2007;25:754-6.
57. Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere J, Benamouzig R, et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Brit J Cancer. 2006;94:1823-32.
58. Nanashima A, Shibata K, Nakayama T, Tobinaga S, Araki M, Kunizaki M, et al. Clinical significance of microvessel count in patients with metastatic liver cancer originating from colorectal carcinoma. Ann Surg Oncol. 2009;16: 2130-7.
59. de Jong KP, Gouw AS, Peeters PM, Bulthuis M, Menkema L, Porte RJ, et al. p53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression. Clin Cancer Res. 2005;11:4067-73.
60. Lee J-C, Chow N-H, Wang S-T, Huang S-M. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer. 2000;36:748-53.
61. Tokunaga T, Oshika Y, Abe Y, Ozeki Y, Sadahiro S, Kijima H, et al. Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer. 1998;77:998-1002.
62. Berney CR, Yang JL, Fisher RJ, Russell PJ, Crowe PJ. Vascular endothelial growth factor expression is reduced in liver metastasis from colorectal cancer and correlates with urokinase-type plasminogen activator. Antican Res. 1998;18:973-7.
63. Kim J, Takeuchi H, Lam ST, Turner RR, Wang H-J, Kuo C, et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol. 2005;23:2744-53.
64. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006;107:1761-7.
65. Kim J, Mori T, Chen SL, Amersi FF, Martinez SR, Kuo C, et al. Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg. 2006;244:113-20.
66. Yoshitake N, Fukui H, Yamagishi H, Sekikawa A, Fujii S, Tomita S, et al. Expression of SDF-1a and nuclear CXCR4 predicts lymph node metastasis in colorectal cancer. Br J Cancer. 2008;98:1682-9.
67. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161-74.
68. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res. 1994;54:4726-8.
69. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med. 1996;2:461-2.
70. Waas E, Wobbes T, Lomme R, DeGroot J, Ruers T, Hendriks T. Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis. Br J Surg. 2003;90:1556-64.
71. Fang YJ, Lu ZH, Wang GQ, Pan ZZ, Zhou ZW, Yun JP, et al. Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorect Dis. 2009;24:875-84.
72. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, β-catenin, and ZEB1 in malignant progression of cancer. Cancer Metast Rev. 2009;28:151-66.
73. Dorudi S, Hanby A, Poulsom R, Northover J, Hart I. Level of expression of E-cadherin mRNA in colorectal cancer correlates with clinical outcome. Br J Cancer. 1995;71:614.
74. Dorudi S, Sheffield J, Poulsom R, Northover J, Hart I. E-cadherin expression in colorectal cancer. An immunocytochemical and in situ hybridization study. Am J Pathol. 1993;142:981.
75. Karamitopoulou E, Zlobec I, Patsouris E, Peros G, Lugli A. Loss of E-cadherin independently predicts the lymph node status in colorectal cancer. Pathology. 2011;43:133-7.
76. Ikeguchi M, Makino M, Kaibara N. Clinical significance of E-cadherin-catenin complex expression in metastatic foci of colorectal carcinoma. J Surg Oncol. 2001;77:201-7.
77. Lennartsson J, Rönnstrand L. Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev. 2012;92:1619-49.
78. Reed J, Ouban A, Schickor FK, Muraca P, Yeatman T, Coppola D. Immunohistochemical staining for c-Kit (CD117) is a rare event in human colorectal carcinoma. Clin Colorect Cancer. 2002;2:119-22.
79. Sammarco I, Capurso G, Coppola L, Bonifazi AP, Cassetta S, Delle Fave G, et al. Expression of the proto-oncogene c-KIT in normal and tumor tissues from colorectal carcinoma patients. Int J Colorect Dis. 2004;19:545-53.
80. Gavert N, Shvab A, Sheffer M, Ben-Shmuel A, Haase G, Bakos E, et al. c-Kit is suppressed in human colon cancer tissue and contributes to L1-mediated metastasis. Cancer Res. 2013;73:5754-63.
81. Gavert N, Conacci-Sorrell M, Gast D, Schneider A, Altevogt P, Brabletz T, et al. L1, a novel target of b-catenin signalling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol. 2005;168:633-42.
82. Boo Y-J, Park J-M, Kim J, Chae Y-S, Min B-W, Um J-W, et al. L1 expression as a marker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer. Ann Surg Oncol. 2007;14:1703-11.
83. Attoub S, Rivat C, Rodrigues S, Van Bocxlaer S, Bedin M, Bruyneel E, et al. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. Cancer Res. 2002;62:4879-83.
84. Tabernero J, Garcia-Carbonero R, Cassidy J, Sobrero A, Van Cutsem E, Kohne CH, et al. Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. Clin Cancer Res. 2013;19:2541-50.
85. Carrato A, Swieboda-Sadlej A, Staszewska-Skurczynska M, Lim R, Roman L, Shparyk Y, et al. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. J Clin Oncol. 2013;31:1341-7.
86. Desch CE, Benson AB, Somerfield MR, Flynn PJ, Krause C, Loprinzi CL, et al. Colorectal cancer surveillance: 2005 update of an American society of clinical oncology practice guideline. J Clin Oncol. 2005;23:8512-9.
87. Broll R, Erdmann H, Duchrow M, Oevermann E, Schwandner O, Markert U, et al. Vascular endothelial growth factor (VEGF) - a valuable serum tumour marker in patients with colorectal cancer? Eur J Surg Oncol (EJSO). 2001;27:37-42.
88. Kumar H, Heer K, Lee P, Duthie GS, MacDonald AW, Greenman J, et al. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res. 1998;4:1279-85.
89. Hyodo I, Doi T, Endo H, Hosokawa Y, Nishikawa Y, Tanimizu M, et al. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer. 1998;34:2041-5.
90. Maurel J, Nadal C, Garcia-Albeniz X, Gallego R, Carcereny E, Almendro V, et al. Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. Int J Cancer. 2007;121:1066-71.
91. Tutton MG, George ML, Eccles SA, Burton S, Swift RI, Abulafi A. Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients. Int J Cancer. 2003;107:541-50.
92. Langenskiöld M, Holmdahl L, Falk P, Ivarsson M-L. Increased plasma MMP-2 protein expression in lymph node-positive patients with colorectal cancer. Int J Colorect Dis. 2005;20:245-52.
93. Wilmanns C, Grossmann J, Steinhauer S, Manthey G, Weinhold B, Schmitt-Gräff A, et al. Soluble serum E-cadherin as a marker of tumour progression in colorectal cancer patients. Clin Exp Metast. 2004;21:75-8.
94. Velikova G, Banks R, Gearing A, Hemingway I, Forbes M, Preston S, et al. Serum concentrations of soluble adhesion molecules in patients with colorectal cancer. Br J Cancer. 1998;77:1857.